China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
PositiveHealth

China's Innovent has made headlines by partnering with Takeda in a deal that could be worth up to $11.4 billion. This collaboration highlights the growing trend of Chinese companies joining forces with international pharmaceutical giants to enhance their global presence and leverage the innovative drug development happening in China. Such partnerships are crucial as they not only boost the companies involved but also promise to bring new treatments to patients worldwide.
— Curated by the World Pulse Now AI Editorial System